Category: Q&A

Spotlight on a CRO: Interview with the Team of Scientists behind NeoGenomics Pharma Services.

NeoGenomics is a cancer diagnostics and pharma services company serving pharmaceutical companies and academic centers. They specialize in diagnostic, prognostic and predictive testing using the most innovative technologies. The company opened its doors in 2002 in Fort Myers, FL, and...

/ July 8, 2020

Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.

Dr. Nina Radosevic-Robin, MD, is a Board-Certified Surgical/Molecular Pathologist at Centre Jean Perrin, a Sr. Scientist within the Unit 1240 of French National Institute for Medical Research (INSERM), and a Lecturer in Molecular Oncology and Protein Science at the University...

/ June 22, 2020

Why is Digital Spatial Profiling Critical to Studying Sarcomas? Q&A with Dr. Troy McEachron, Ph.D

“Whereas the EWS specimens tended to have very simple genomes, the osteosarcoma specimens looked like a hand grenade had gone off in the genome. These were the most fragmented and complex genomes I had ever seen”. Troy McEachron, Ph.D The first...

/ June 15, 2020

Solid Organ Transplantation and the Immunology of Rejection. Q&A with GeoMx® Digital Spatial Profiler Grant Winner Dr. Fadi Issa

"Cancer immunotherapy and transplantation are basically the same field; one’s just the flip side of the other". Dr. Fadi Issa Have you ever been to Oxford? Situated in the gorgeous English countryside, 56 miles northwest of London, Oxford is the...

/ June 8, 2020

Searching for New Biomarkers to Prevent Organ Transplant Rejection. Q&A with HOT Panel Grant Winner Dr. Evan Farkash

Bob’s first question to me was: “How much do you want to learn about kidney pathology?” My response was that I wanted to learn as much as I could, and I don’t think I have stopped learning since then.” Dr....

/ June 1, 2020